Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Zinc in Infant Bacterial Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Evidence of possible serious bacterial infection, defined as a CRP \>= 12 mg/L and any one of the following clinical features:~Fever (axillary temperature \>= 37.5 degrees C) or hypothermia (axillary temperature \<35.5 degrees C).~Lethargic or unconscious. No attachment to the breast in breast fed infants. No suckling in breast fed infants. Convulsions in the present episode. Bulging fontanel.~* History of acute refusal of feed in the present episode.~* Acute history of excessive cry or irritability in the present episode.~* Fast breathing defined as \>= 60 breaths/minute (on second count) for infants \< 2 months and \>= 50 breaths/min in infants 2 months up to 4 months.~* Grunting in the absence of any non infective cause.~* Cyanosis in the absence of any non infective cause.~* Severe chest in drawing.~* Unexplained shock.~* Diarrhea in present episode.~Exclusion Criteria:~* Congenital malformations e.g. hydrocephalus, structural CNS malformation.~* Severe birth asphyxia defined as:~  * One minute APGAR (if available) of \< 4/10.~ * CT scan or MRI or EEG abnormalities if available suggestive of hypoxic ischemic encephalopathy.~* Known structural defects, which interfere with feeding, e.g.cleft palate esophageal abnormalities, intestinal atresia and stenosis, malrotation of the gut,anorectal malformation.~* Subjects requiring ventilation or ionotropic support.~* History of diarrhea in the present episode.~* Known inborn error of metabolism.~* Chronic disorders of other organs e.g. neonatal cholestasis, chronic renal failure, pre-existing seizure disorder.~* Infants born of known HIV mothers.~* Clinical suspicion of necrotising enterocolitis.~* Congenital heart disease.~* Any CVS malformation:~  * Congenital heart disease.~ * Cyanosis before present episode.~ * Presence of murmur \> grade 3/6.~* Ambiguous genitalia.~* Known chromosomal abnormality.~* Infants requiring exchange transfusion.

- Gender: ALL
- Minimum Age: 1 Week
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Zinc (Type: EXPERIMENTAL): Administration of zinc sulphate every day during illness
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).